Literature DB >> 19212791

Sentinel node biopsy in patients with previous breast aesthetic surgery.

Julia Rodriguez Fernandez1, Stefano Martella, Giuseppe Trifirò, Mujgan Caliskan, Camelia Chifu, Fabricio Brenelli, Edoardo Botteri, Fabio Rossetto, Nicole Rotmensz, Mario Rietjens, Paolo Veronesi.   

Abstract

BACKGROUND: Sentinel lymph node biopsy (SLNB) is the standard method for axillary staging of early breast cancer. Recent studies have focused on questioning the initial contraindication to the technique. There has been insufficient data to recommend SLNB in patients with previous aesthetic breast surgery.
MATERIALS AND METHODS: Between April 2001 and June 2007, 70 patients with previous breast aesthetic surgery underwent SLNB. Fifty had a previous breast augmentation and 20 had breast reduction mammoplasty. All patients underwent lymphoscintigraphy with 99Tc according to our standard technique and sentinel node was identified in all cases.
RESULTS: Mean age at cosmetic surgery was 38 years. Mean number of years from aesthetic surgery to the development of the tumour was 10 years. Forty-nine patients underwent conservative breast surgery and 21 patients underwent mastectomy. The sentinel node identification rate was 100%. SLN was positive in 23 patients (32%); there were 18 cases with macrometastasis and 7 cases with micrometastasis. After median follow-up of 19 months, no axillary recurrences have been observed. We observed two ipsilateral local recurrences, one contralateral tumour and one patient developed lung metastasis.
CONCLUSIONS: Past history of breast augmentation or reduction is not a contraindication to SLNB technique.

Entities:  

Mesh:

Year:  2009        PMID: 19212791     DOI: 10.1245/s10434-009-0349-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ.

Authors:  Ahmed Yahia Al-Ameer; Sahar Al Nefaie; Badria Al Johani; Ihab Anwar; Taher Al Tweigeri; Asma Tulbah; Mohmmed Alshabanah; Osama Al Malik
Journal:  World J Clin Oncol       Date:  2016-04-10

Review 2.  Current status of sentinel lymph-node biopsy in patients with breast cancer.

Authors:  Gang Cheng; Stephanie Kurita; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-11       Impact factor: 9.236

3.  Sentinel Lymph Node Biopsy in Early Breast Cancer: The Experience of the European Institute of Oncology in Special Clinical Scenarios.

Authors:  Antonio Toesca; Alberto Luini; Paolo Veronesi; Mattia Intra; Oreste Gentilini
Journal:  Breast Care (Basel)       Date:  2011-06-03       Impact factor: 2.860

4.  The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Francesco Giammarile; Naomi Alazraki; John N Aarsvold; Riccardo A Audisio; Edwin Glass; Sandra F Grant; Jolanta Kunikowska; Marjut Leidenius; Valeria M Moncayo; Roger F Uren; Wim J G Oyen; Renato A Valdés Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

5.  A case of synchronous multiple bilateral breast cancer after breast augmentation.

Authors:  Shinya Yamamoto; Takashi Chishima; Fumi Harada; Yuka Matsubara
Journal:  Springerplus       Date:  2015-12-23

6.  Sentinel node mapping for breast cancer: current situation.

Authors:  Sergi Vidal-Sicart; Renato Valdés Olmos
Journal:  J Oncol       Date:  2012-08-15       Impact factor: 4.375

7.  Lymphatic mapping could not be impaired in the presence of breast carcinoma and coexisting small lymphocytic lymphoma.

Authors:  Sebastian Arana; Jorge Vasquez-Del-Aguila; Martin Espinosa-Bravo; Vicente Peg; Isabel T Rubio
Journal:  Am J Case Rep       Date:  2013-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.